Test for the Early Detection of Ovarian Cancer

Ronny Drapkin, MD, PhD & Jarrod Marto, PhD

Ronny Drapkin, MD, PhD & Jarrod Marto, PhD

About Project

Biomarker discovery in tissue proximal fluids


High-grade serous ovarian carcinomas, the most common subtype of ovarian cancer, originate not in the ovaries but in fallopian tube secretory epithelial cells. In order to determine which detectable biomarkers accompany this cell type’s transition from normal to cancerous, Drs. Drapkin and Marto have established cell lines with different cancer causing genetic mutations that they can monitor over time. This way, they can compare a set of proteins secreted by benign fallopian tube secretory epithelial cells with those secreted by cells as they become malignant. Proteins that are secreted only by tumor cells, or that are secreted in larger amounts by tumor cells, may be viable biomarkers. Using this method they have identified three proteins that seem to be especially promising candidates for diagnostic use.




Q: How would you explain the broader significance of your research to a layperson?

A: Our lab (and the Penn Ovarian Cancer Research Center) is entirely focused on finding new ways to detect and treat ovarian cancer. We use a multi-pronged approach to achieve this goal. We try to understand some of the basic fundamental biology that makes ovarian cancer tick and leverage that knowledge towards ways to help patients. In regards to early detection, developing a tool that can achieve this is the holy grail in the field.

Q: What is the job of a scientific medical researcher on a day to day basis? For example, what did you do this morning?

A: The daily job of a scientist depends on the stage of his/her career. A graduate student spends most of their days (and sometimes nights) working on ‘the bench’ (in the lab) doing experiments and troubleshooting problems. A postdoctoral fellow also spends most of his or her time at the bench but with greater responsibility and with an eye to the future. It is as a postdoctoral fellow that you have to hone your writing and presenting skills as these will be critical in achieving and sustaining an independent career. As a lab head or principle investigator (PI), your job is to provide the scientific intellectual thrust being conducted by the graduate students and postdocs. As the PI you also spend a lot of time writing grants and fundraising for one’s own lab.

Q: Would you say that you chose ovarian cancer research or ovarian cancer research chose you?

A: When I was a postdoctoral fellow I was working in a lab that studies BRCA1, the gene responsible for many hereditary forms of breast and ovarian cancer. However, at the time, most of the focus was on breast cancer. Ovarian cancer was considered a ‘black box’ and few resources existed to support its research. Being a physician, I found this disturbing because it was such a devastating disease. I wanted to see the ‘concert for the cure’ and the ‘race for the cure’ exist for ovarian cancer just like for breast cancer. Scientifically, I thought ovarian cancer represented a great opportunity to make significant contributions and I began by attacking the most vexing problem, the lack of an early detection tool.

Q: Who have been your most influential mentors throughout your career?

A: I have been fortunate to work with some amazing scientists during my career. My undergraduate thesis advisor, Dr. James Haber, a member of the National Academy of Science, showed me how simple model systems can help us ask and answer big questions that are relevant to the human condition. My graduate adviser, Dr. Danny Reinberg, a Howard Hughes Medical Institute investigator and National Academy member, taught me the importance of hard work and being rigorous in my approach to science. My postdoctoral mentor, Dr. David Livingston, also a National Academy member, taught me the importance of being creative and thinking ‘outside the box’. My clinical mentor, Dr. Chris Crum, taught me the importance of understanding unmet medical needs and letting that drive my science. I have been tremendously fortunate to have these scientists as my mentors and colleagues.

Q: What was your proudest moment or biggest achievement during your career thus far?

A: My proudest moments include insights that I made in all three phases of my training:
1) As a graduate student I made the link between transcriptional regulation and DNA repair. We found that the xeroderma pigmentosum proteins involved in DNA repair were also playing vitally important roles in regulating gene expression.
2) As a postdoctoral fellow I showed that the HE4 biomarker is a protein that is enzymatically modified and secreted by the most common forms of ovarian cancer. These observations contributed to its eventual approval as an ovarian cancer biomarker by the FDA. I was also involved in the cloning of BRIP1/FANCJ, an important gene in the BRCA network of DNA repair proteins and showed that it is a protein that can unwind DNA.
3) As an independent investigator working together with my clinical mentor, Chris Crum, we showed that the fallopian tube is the likely site of origin for a majority of high-grade serous ovarian carcinomas. This has proven to be a paradigm shift in the field and motivated my lab to develop novel experimental model systems to study the fallopian tube and figure out what makes it susceptible to becoming a cancer.

Q: What are your short-term and long-term visions or hopes for the future in relation to science and ovarian cancer research?

A: The recent UKCTOCS study on longitudinal screening for ovarian cancer raises the hope that we might be on the road towards a screening approach that could impact mortality. That study will conclude in 2018 and so I hope that within five years we will have a better grasp on how screening can help and possibly identify other biomarkers that will further contribute to this goal.

Q: In addition to being an individual grant recipient, you are funded by the TW Rita Kirpalani Consortium Grant. Please tell us more about the Tina’s Wish Research Consortium’s collaborative approach to science.

A: By establishing The Tina’s Wish Consortium, investigators from five different research institutions began to collaborate. The nucleating force is a collection of well annotated tumor samples that all the investigators are using to study different approaches for early detection. The hope is that the depth of information collected on these tumor samples by allowing everyone to apply their unique scientific approach will be more informative than each investigator working in a vacuum.

Q: Have you been personally affected by ovarian cancer?

A: One of my good friends in high school lost his mother to ovarian cancer when we were teenagers. Cancer was more of a mystery to me at that time but I vividly remember how devastating it was for the family. Later on, as an adult, when I lost my two in-laws to cancer, I came to fully appreciate how cancer affects an entire family, not just the patient, and how good compassionate care can really help a whole family and community cope with the challenge of cancer treatment and the loss of a loved one.

Q: What do you do when you are not working?

A: I enjoy time with my wife and two kids. I also enjoy cycling, skiing, playing basketball with my daughter who is on the girls varsity basketball team, and, more recently, some ‘wicked good’ ping-pong games with my son. I am also a huge New England sports fan and love to go to games when possible.

Q: What’s the last Book that you read?

A: The Marian by Andy Weir; Retribution by David Hagberg; Ender’s Game by Orson Scott Card; For the Love of Enzymes by Arthur Kornberg.

Q: Tell us a fun fact about yourself.

A: I was born in Chile, lived in Israel for 7 years, before moving to NYC where I started elementary school in 2nd grade.

Back to Current Research